| scholarly article | Q13442814 |
| P50 | author | Gregory A. Denomme | Q42396875 |
| Nadine Shehata | Q64022699 | ||
| P2093 | author name string | Franz F Wagner | |
| Willy A Flegel | |||
| William J Lane | |||
| Maryse St-Louis | |||
| Lilian Castilho | |||
| Christopher A Tormey | |||
| Margaret A Keller | |||
| Gary Stack | |||
| France Pirenne | |||
| Ellen B Klapper | |||
| Dan A Waxman | |||
| Wm Andrew L Heaton | |||
| P2860 | cites work | Pathogenesis and mechanisms of antibody-mediated hemolysis | Q26801809 |
| National marrow donor program session: donor issues | Q26851349 | ||
| Polymorphism of the h allele and the population frequency of sporadic nonfunctional alleles | Q28236328 | ||
| Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle | Q28270623 | ||
| Molecular immunohaematology round table discussions at the AABB Annual Meeting, Boston 2012. | Q33690911 | ||
| It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group. | Q35171108 | ||
| Next-generation sequencing is a credible strategy for blood group genotyping | Q35227620 | ||
| Integration of red cell genotyping into the blood supply chain: a population-based study | Q35867613 | ||
| Molecular immunohaematology round table discussions at the AABB Annual Meeting, Denver 2013 | Q36187389 | ||
| Implementing mass-scale red cell genotyping at a blood center | Q36277665 | ||
| Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. | Q36539925 | ||
| The BloodGen project: toward mass-scale comprehensive genotyping of blood donors in the European Union and beyond | Q36861133 | ||
| Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients | Q37136211 | ||
| Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand | Q37588930 | ||
| The promise and challenges of next-generation genome sequencing for clinical care | Q38161772 | ||
| Is Next Generation Sequencing the future of blood group testing? | Q38199281 | ||
| Extended blood group molecular typing and next-generation sequencing | Q38256494 | ||
| Considerations of red blood cell molecular testing in transfusion medicine | Q38586467 | ||
| Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time | Q40021926 | ||
| Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? | Q40337060 | ||
| Transcriptional regulation of the human ABO histo-blood group genes is dependent on the N box upstream of the proximal promoter | Q40483573 | ||
| Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region | Q40911589 | ||
| Molecular immunohaematology round table discussions at the AABB Annual Meeting, Philadelphia 2014. | Q42396851 | ||
| Genotyping patients' and donors' blood groups for efficient blood therapy | Q42430785 | ||
| Why do we use serological blood group phenotype determination in chronically transfused patients? | Q42508607 | ||
| International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). | Q42603051 | ||
| ABO genotyping: the quest for clinical applications | Q43051362 | ||
| Comment on "Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand". | Q43131903 | ||
| Overcoming methodical limits of standard RHD genotyping by next-generation sequencing | Q43456792 | ||
| Transfusion support of autoimmune hemolytic anemia: how could the blood group genotyping help? | Q43708402 | ||
| Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma | Q44639381 | ||
| Toward extended phenotype matching: a new operational paradigm for the transfusion service | Q46040794 | ||
| High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors | Q46358211 | ||
| HEA BeadChip™ technology in immunohematology | Q50280449 | ||
| Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study). | Q50435948 | ||
| What is the value of a blood type? | Q86164310 | ||
| The promise of extended donor antigen typing | Q86679997 | ||
| Blood group genotyping: faster and more reliable identification of rare blood for transfusion | Q86946003 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 557-565 | |
| P577 | publication date | 2016-07-29 | |
| P1433 | published in | Blood transfusion = Trasfusione del sangue | Q26842792 |
| P1476 | title | Molecular immunohaematology round table discussions at the AABB Annual Meeting, Anaheim 2015 | |
| P478 | volume | 14 |
Search more.